title: Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction.
abstract: BACKGROUND
  Cryopreservation of oocytes or embryos preceded by controlled ovarian stimulation (COS) can increase the chance of future pregnancy in women with breast cancer who risk therapy-induced ovarian failure. In women with estrogen-receptor (ER) positive breast cancer, alternative COS protocols with tamoxifen or letrozole are being used to theoretically inhibit breast cancer growth during COS.
  
  
  OBJECTIVE
  To assess the effects of tamoxifen or letrozole, in addition to standard COS protocols, on the breast cancer-free interval in premenopausal women with ER positive breast cancer who undergo COS for embryo or oocyte cryopreservation.
  
  
  METHODS
  We searched the Ovid Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid EMBASE, Ovid PsycINFO, and EBSCOhost CINAHL. We applied no limitations in year of publication or language. In addition, we searched trial registers for ongoing and registered trials, conference abstracts, and sources of grey literature. The search was conducted in January 2013.
  
  
  METHODS
  Randomised trials comparing different COS protocols in women with breast cancer were eligible for inclusion.
  
  
  METHODS
  Two review authors independently scanned the titles, abstracts, or both sections according to Cochrane guidelines. If data to include were provided, data extraction would have been independently performed by two review authors by using forms designed according to Cochrane guidelines.
  
  
  RESULTS
  No randomised controlled trials were found that met the inclusion criteria.
  
  
  CONCLUSIONS
  COS schedules with the additional use of tamoxifen or letrozole are commonly chosen as an alternative regimen in young women with ER positive breast cancer who undergo COS for oocyte or embryo cryopreservation. No randomised controlled trials support the idea that these alternative COS schedules are superior to standard COS.
authors.affiliation: Center for Reproductive Medicine, Department of Obstetrics and Gynaecology, Academic Medical Center University of Amsterdam, Meibergdreef 9, Amsterdam, Netherlands, 1105 AZ.
authors.forename: Taghride
authors.initials: T
authors.lastname: Dahhan
authors.forename: Eva
authors.initials: E
authors.lastname: Balkenende
authors.forename: Madelon
authors.initials: M
authors.lastname: van Wely
authors.forename: Sabine
authors.initials: S
authors.lastname: Linn
authors.forename: Mariëtte
authors.initials: M
authors.lastname: Goddijn
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D015925:Cryopreservation; D004622:Embryo, Mammalian; D005260:Female; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000627:therapeutic use*; D009865:Oocytes; D011247:Pregnancy; D011960:Receptors, Estrogen / Q000378:metabolism; D027724:Reproductive Techniques, Assisted; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D009570:Nitriles; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D014230:Triazoles; D013629:Tamoxifen; D000077289:Letrozole